Publication

Oral antitumor activity in murine L1210 leukemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine (ara-C)

Journal Paper/Review - Jan 1, 1996

Units
PubMed
Contact

Citation
Schwendener R, Horber D, Odermatt B, Schott H. Oral antitumor activity in murine L1210 leukemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine (ara-C). J Cancer Res Clin Oncol 1996; 122:102-108.
Type
Journal Paper/Review (English)
Journal
J Cancer Res Clin Oncol 1996; 122
Publication Date
Jan 1, 1996
Pages
102-108
Brief description/objective

The oral cytostatic activity in L1210 mouse leukaemia of the two new N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine (AraC), N4-hexadecyl- and N4-octadecyl-1-beta-D-arabinofuranosylcytosine (NH-AraC, NO-AraC) was investigated. In contrast to AraC, both derivatives were highly cytostatic after oral application as liposome formulations. With treatment schedules of five consecutive dosages or with two applications on days 1 and 4 after intravenous tumour cell inoculation with a total dose of 470-1000 mg/kg NH-AraC or NO-AraC, 70%-100% of the treated animals were cured. The lethal dose in healthy ICR mice after a single intraperitoneal application, corresponding to the LD50, was 524 mg/kg for NO-AraC, whereas NH-AraC proved to be less toxic. The haematological toxicity remained moderate for both drugs with a mild leucopenia and a drop in platelet counts, which recovered 4-6 days after treatment. The erythrocytes were not affected and haemolytic toxicities were absent. As non-haematological toxicities, at high drug concentrations, a pronounced atrophy of the rapidly dividing epithelia of the small intestines and of the white pulp of the spleen were observed. The blood levels of NH-AraC given orally reached values comparable to those after parenteral application of a four-times lower dose of NH-AraC, suggesting a moderate bioavailability. Thus, these two lipophilic derivatives of AraC are compounds with a potential for the oral treatment of malignant diseases.